Our Pricing

What Is Foundayo (Orforglipron)?

Published on: June 03, 2026

If you're wondering what is Foundayo (orforglipron) UK, you're researching one of the most anticipated oral weight loss medications currently in development. Foundayo contains orforglipron, a once-daily oral GLP-1 receptor agonist designed to offer similar weight loss benefits to injectable treatments without the need for needles. While Foundayo is not yet licensed in the UK, proven alternatives are available now through Cured Pharmacy with transparent pricing and expert clinical support.

Understanding Foundayo: How Orforglipron Works

Foundayo (orforglipron) is an investigational oral medication that belongs to the GLP-1 receptor agonist class, the same family as Wegovy and Mounjaro [1]. Unlike injectable GLP-1 treatments, orforglipron is designed as a once-daily tablet, addressing one of the most common barriers to weight loss medication adherence: needle anxiety.

Orforglipron works by mimicking the natural hormone GLP-1 (glucagon-like peptide-1), which regulates appetite, slows gastric emptying, and improves insulin sensitivity [1]. In phase 2 clinical trials, participants taking orforglipron 45mg daily achieved an average weight reduction of 14.7% over 36 weeks, demonstrating clinically meaningful efficacy without injections [2].

The medication is being developed by Eli Lilly, the same manufacturer behind Mounjaro (tirzepatide). While Foundayo shows promise, it remains under investigation and has not yet received MHRA approval for use in the UK.

Foundayo Clinical Trial Results and Efficacy

Phase 2 trial data published in 2023 showed that orforglipron produced dose-dependent weight loss, with higher doses achieving greater reductions [2]. Participants on the 45mg daily dose lost an average of 14.7% of their baseline body weight over 36 weeks, whilst those on 36mg lost approximately 12.6% [2].

These results position orforglipron as potentially competitive with existing injectable GLP-1 medications, though direct head-to-head trials have not yet been conducted. For context, semaglutide (Wegovy) achieved an average 15% weight reduction over 68 weeks in the STEP 1 trial, whilst tirzepatide (Mounjaro) demonstrated up to 22.5% reduction in SURPASS trials [3][4].

Phase 3 trials are currently ongoing to establish long-term safety, efficacy, and cardiovascular outcomes. Until these trials conclude and regulatory approval is granted, orforglipron remains unavailable for prescription in the UK.

Expected Timeline for UK Availability

Eli Lilly has not yet announced a specific timeline for MHRA submission or UK launch. Based on typical drug development pathways, Foundayo is unlikely to be available in the UK before 2026, subject to successful completion of phase 3 trials and regulatory review. Patients seeking weight loss treatment now should consider currently licensed alternatives available through UK pharmacies.

Foundayo vs Injectable Weight Loss Medications

The primary advantage of Foundayo over existing treatments is its oral formulation. Many patients find daily injections inconvenient or anxiety-inducing, making oral alternatives highly desirable. However, injectable GLP-1 medications currently offer proven, licensed options with extensive real-world safety data.

Wegovy (semaglutide) and Mounjaro (tirzepatide) are both once-weekly injections licensed by the MHRA for chronic weight management in adults with a BMI of 30 or above, or 27 with weight-related comorbidities [3][4]. These medications have been prescribed to millions of patients globally, with well-established efficacy and safety profiles.

Oral semaglutide tablets (marketed as Rybelsus for type 2 diabetes and recently as Wegovy Oral Tablets for weight loss) are already available in the UK, offering a needle-free option for patients who prefer tablets. These provide a licensed alternative whilst Foundayo remains in development.

Choosing Between Oral and Injectable Treatments

Your UK prescriber will assess your medical history, weight loss goals, and personal preferences to recommend the most suitable treatment. Injectable medications may offer higher efficacy for some patients, whilst oral options provide convenience and eliminate injection-related concerns. At Cured Pharmacy, our clinical team can guide you through licensed alternatives that match your needs today.

What Is Foundayo Orforglipron Side Effects Profile

In clinical trials, orforglipron's side effect profile was consistent with other GLP-1 receptor agonists [2]. The most commonly reported adverse effects included nausea (reported in approximately 50% of participants), vomiting, diarrhoea, and constipation. These gastrointestinal symptoms were typically mild to moderate and decreased over time as patients adjusted to the medication.

Serious adverse events were rare in phase 2 trials, though longer-term safety data from phase 3 studies will be essential before regulatory approval. As with all GLP-1 medications, orforglipron carries theoretical risks including pancreatitis, gallbladder disease, and thyroid C-cell tumours (observed in rodent studies but not confirmed in humans) [1][2].

Patients considering any GLP-1 medication should undergo thorough medical screening. At Cured Pharmacy, every prescription requires a comprehensive clinical assessment by a UK-registered prescriber to ensure safety and suitability.

UK-Licensed Alternatives to Foundayo Available Now

Whilst Foundayo remains in development, several proven weight loss medications are available through UK-registered online pharmacies. These include injectable GLP-1 treatments and oral fat absorption inhibitors, all licensed by the MHRA for chronic weight management.

Wegovy (semaglutide) is a once-weekly injection that achieved an average 15% weight reduction in clinical trials and is available from £135.00 at Cured Pharmacy [3]. Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist, demonstrated up to 22.5% weight loss in the SURPASS-3 trial and is priced from £135.00 [4]. For patients preferring daily injections, Saxenda (liraglutide) offers an established option from £135.00.

Oral alternatives include Wegovy Oral Tablets (semaglutide pill) from £135.00 providing needle-free GLP-1 therapy. Orlistat-based medications (Xenical, Alli, Orlos) work through a different mechanism by blocking fat absorption and are available from £135.00. All treatments require a clinical assessment by a UK prescriber before dispensing.

Starting Your Weight Loss Journey Today

At Cured Pharmacy, you can complete a free online consultation in under three minutes. Our UK-registered clinical team will review your medical history, assess your suitability for treatment, and recommend the most appropriate licensed medication. With transparent upfront pricing, discreet packaging, and lowest prices guaranteed, you can start your weight loss journey with confidence whilst Foundayo completes its development pathway.

How to Access Weight Loss Treatment Through Cured Pharmacy

Accessing prescription weight loss medication through Cured Pharmacy is straightforward and completely confidential. Start by completing our online medical questionnaire, which takes under three minutes and covers your medical history, current medications, and weight loss goals. This information is reviewed by a UK-registered prescriber who will assess your suitability for treatment.

If approved, your prescription is sent electronically to our UK-registered pharmacy (GPhC 9012511), where your medication is dispensed and dispatched in discreet packaging. Most orders are delivered within 1-3 working days via tracked courier. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees every prescription to ensure safety and compliance with UK regulations.

Cured Pharmacy offers transparent upfront pricing with no hidden fees. You'll see the exact cost before completing your consultation, and we guarantee the lowest prices in the UK. Our clinical team is available on (+44) 116 4646009 if you have questions about your treatment or need support during your weight loss journey.

Scientific References

1. Frias, J. P., et al. (2023). Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-ranging, phase 2 study. The Lancet, 402(10417), 472–483. https://doi.org/10.1016/S0140-6736(23)01302-4 [accessed 13 August 2026]
2. Rosenstock, J., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet, 402(10401), 529–544. https://doi.org/10.1016/S0140-6736(23)01053-X [accessed 13 August 2026]
3. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
4. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.